| Literature DB >> 33561845 |
Roberta Visone1, Giovanni S Ugolini1, Daniela Cruz-Moreira1, Simona Marzorati2, Stefano Piazza3, Enrico Pesenti2, Alberto Redaelli1, Matteo Moretti4,5,6, Paola Occhetta1, Marco Rasponi1.
Abstract
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing withdrawal. The development of relevantin vitromodels resembling the human heart recently opened the path towards a more accurate detection of drug-induced human cardiac toxicity early in the drug development process. Organs-on-chip have been proposed as promising tools to recapitulatein vitrothe key aspects of thein vivocardiac physiology and to provide a means to directly analyze functional readouts. In this scenario, a new device capable of continuous monitoring of electrophysiological signals from functionalin vitrohuman hearts-on-chip is here presented. The development of cardiac microtissues was achieved through a recently published method to control the mechanical environment, while the introduction of a technology consisting in micro-electrode coaxial guides allowed to conduct direct and non-destructive electrophysiology studies. The generated human cardiac microtissues exhibited synchronous spontaneous beating, as demonstrated by multi-point and continuous acquisition of cardiac field potential, and expression of relevant genes encoding for cardiac ion-channels. A proof-of-concept pharmacological validation on three drugs proved the proposed model to potentially be a powerful tool to evaluate functional cardiac toxicity. Creative Commons Attribution license.Entities:
Keywords: cardiac model; drug screening; electrophysiology; field potential; heart-on-chip; mechanical stimulation; organs-on-chip
Mesh:
Year: 2021 PMID: 33561845 DOI: 10.1088/1758-5090/abe4c4
Source DB: PubMed Journal: Biofabrication ISSN: 1758-5082 Impact factor: 9.954